.jpg?format=webp&width=780)
The study examined the effects of istaroxime in patients hospitalized for acute heart failure (AHF) related to the Society for Cardiovascular Angiography and Interventions (SCAI) stage B pre‐cardiogenic shock (CS). Sixty patients with AHF without acute myocardial infarction with pre‐CS, defined as systolic blood pressure (SBP) < 90 mmHg without hypoperfusion, venous lactate > 2 mmol/L and/or mechanical or inotropic support, were randomized to istaroxime 1.0 ‐1.5 μg/kg/min or placebo for 24 hours. In phase 2a study of patients with AHF related pre‐CS istaroxime improved BP and some echocardiography measures associated with HF and were well tolerated.
Like
Save
Share